Waters Corporation is expected to report Q3 2026 revenue of $1.75 billion and adjusted earnings per share of $3.99, with the stock currently trading at $462.72, nearly aligned with the average analyst price target of $466.43.
Investors are primarily focused on the integration and organic performance of the newly acquired Becton Dickinson biosciences and diagnostics units, which have significantly scaled the company's footprint this year.
This report marks a critical test for the $17.5 billion merger, with management previously guiding for 8-10% organic revenue growth in constant currency for the period. Strong performance in the legacy Analytical Sciences division and early cross-selling synergies are expected to help offset integration complexities and a challenging capital spending environment in China.